Vascular Pharmacology

Papers
(The H4-Index of Vascular Pharmacology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
The transfer of gut microbiota/metabolites from children to mice affects cardiometabolic development and induces sex-dimorphism in recipients115
Prevalence of antiphospholipid antibodies in COVID-19 patients: A meta-analysis76
Patterns of medication use and potential drug-drug interactions in post-PCI patients: A study from Iran46
The MEK-ERK-Egr-1 axis and its regulation in cardiovascular disease37
Corrigendum to “Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis” [Vascular Pharmacology 155 (2024) 10731
Graphical abstract TOC30
Biobanks: The unmet need in heart failure management29
Graphical abstract TOC27
Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study26
Molecular mechanisms of flavonoids in myocardial ischemia reperfusion injury: Evidence from in-vitro and in-vivo studies25
ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score24
Animal experimental models of ischemic limbs – A systematic review23
Prevention of cardiovascular complications in elderly cancer patients23
Editorial Board22
Editorial Board22
Diabetes and vascular disease: New therapeutic avenues20
A random shuffle method to expand a narrow dataset: A heart failure cohort example19
Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes19
Exploiting endothelial functions in bone regenerative medicine18
Optical stimulation of endothelial colony forming cells plated on light-sensitive conjugated polymers induces a TRPV1-mediated increase in intracellular Ca2+ concentration18
Doxorubicin-induced cardiotoxicity enhance SARS-CoV-2 infection susceptibility in human cardiomyocytes18
0.071393013000488